Attovia Therapeutics, Inc. SEC filings ATTO

Attovia Therapeutics, Inc. has 56 filings in SEC EDGAR's recent list, going back to Dec 19, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 2, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 2, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Sep 2, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Sep 2, 2026 Sep 2, 2026
8-K Current report
Bylaw or fiscal year change
 Aug 6, 2026 Aug 6, 2026
S-8 Employee stock plan registration Aug 6, 2026 —
424B4 Prospectus Aug 5, 2026 —
EFFECT Filing Aug 4, 2026 —
CERT Filing Aug 4, 2026 —
S-1/A Amended registration statement Aug 4, 2026 —
8-A12B Filing Jul 29, 2026 —
S-1/A Amended registration statement Jul 29, 2026 —
S-1 Registration statement Jul 14, 2026 —
DRS/A Filing Jun 5, 2026 —
DRS/A Filing Feb 12, 2026 —
DRS Filing Dec 19, 2025 —

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ATTO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Carlos, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2058707

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.